Communiqués

29/05 Quest PharmaTech Provides Corporate Update including Voluntary Adoption of CSA Blanket Order 51-93 to File Financial Statements and MD&A on Semi-Annual Basis AQ
27/08/25 Quest PharmaTech Announces Results from AGM AQ
11/06/25 Quest PharmaTech Announces Opposition to OQPBIOM's Acquisition of AdBioTech AQ
02/06/25 Quest PharmaTech Provides Corporate Update AQ
11/10/24 Quest PharmaTech Announces Results from AGM AQ
30/05/24 Quest PharmaTech Announces Filing of 2024 Year End Financial Statements and Restated Fiscal 2023 Financial Statements, and Appointment of New Director AQ
30/01/24 Quest Receives Cash Dividend Payment from OncoQuest AQ
24/01/24 Quest PharmaTech Inc. - Oregovomab Phase III Clinical Study fails futility analysis, Data Safety Monitoring Board Recommends Overall Survival Follow Up for Potential Late Immune Effects and Clinical Benefits AQ
23/01/24 Oregovomab Phase III Clinical Study fails futility analysis; Data Safety Monitoring Board Recommends Overall Survival Follow Up for Potential Late Immune Effects and Clinical Benefits AQ
13/09/23 Quest PharmaTech Provides Corporate Update AQ
14/07/23 Quest PharmaTech Announces Results from AGM AQ
10/07/23 Quest PharmaTech Provides Product Development Update AQ
09/06/23 Quest PharmaTech Provides Corporate Update AQ
07/06/23 Canadian Investment Regulatory Organization Trade Resumption - QPT AQ
06/06/23 Quest PharmaTech Clarifies Agreement in Principle with OQP Bio Inc. AQ
06/06/23 Canadian Investment Regulatory Organization Trading Halt - QPT AQ
02/06/23 Quest PharmaTech Provides Corporate Update AQ
28/09/22 Quest PharmaTech Announces Sale of Bioceltran Investment and Return of Photodynamic Therapy Technology License AQ
21/07/22 Quest PharmaTech Announces Results from AGM AQ
19/04/22 Quest PharmaTech Provides Corporate Update AQ
02/09/21 Quest PharmaTech : September 1, 2021 OncoQuest Pharmaceuticals Inc. Announces First Patient Enrolled in Each of Two Investigator Initiated Clinical Trials of Oregovomab in Combination Therapy for the Treatment of Recurrent Ovarian Cancer PU
01/09/21 Quest PharmaTech : OncoQuest Pharmaceuticals Inc. Announces First Patient Enrolled in Each of Two Investigator Initiated Clinical Trials of Oregovomab in Combination Therapy for the Treatment of Recurrent Ovarian Cancer AQ
08/07/21 Quest PharmaTech : July 7, 2021 Quest PharmaTech Announces Results from AGM PU
07/07/21 Quest PharmaTech : Announces Results from AGM AQ
02/06/21 Quest PharmaTech : June 1, 2021 Quest PharmaTech Announces two presentations by OncoQuest Pharmaceuticals, Inc. at the 2021 Annual Meeting of the American Association of Clinical Oncologists PU
Aucun résultat pour cette recherche